NCT06989307

Brief Summary

This study looks at how many healthcare workers at CHSD hospital developed antibodies against COVID-19 after the second and third waves of the pandemic and after receiving a vaccine. It aims to better understand who might still be at risk of infection, how long immunity lasts after getting COVID or the vaccine, and how reliable previous antibody tests were. Blood samples will be collected from volunteer hospital staff during a one-month period to measure their antibody levels and compare them to earlier results.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
447

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
4 years until next milestone

First Submitted

Initial submission to the registry

May 22, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 25, 2025

Completed
Last Updated

May 25, 2025

Status Verified

May 1, 2025

Enrollment Period

3 months

First QC Date

May 22, 2025

Last Update Submit

May 22, 2025

Conditions

COVID-19COVID-19 Serological TestingCOVID-19 VaccinesHealth PersonnelAntibodies, ViralSeroepidemiologic Studies

Outcome Measures

Primary Outcomes (1)

  • SARS-CoV-2 antibody prevalence (seroprevalence) among healthcare workers at CHSD

    1 month (during the serological testing period)

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study participants will be selected from the staff of the CHSD hospital. The target population includes all hospital personnel, regardless of role or department, who volunteer to participate and provide informed consent for the serological survey.

You may qualify if:

  • \- Volunteers from the hospital staff who have signed a new informed consent form

You may not qualify if:

  • Refusal to participate (no signed consent form)
  • Staff unavailable during the blood sampling period
  • Participation only in the first seroprevalence survey without consent for the second

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

France

Saint-Denis, France, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2025

First Posted

May 25, 2025

Study Start

March 1, 2021

Primary Completion

June 1, 2021

Study Completion

June 1, 2021

Last Updated

May 25, 2025

Record last verified: 2025-05

Locations

FR(1)